ArticleFrontiers in oncology2025
Treatment outcomes of squamous cell carcinoma of the external auditory canal and potential benefit of induction chemotherapy followed by chemoradiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Causative Role for a BRCA2 Germline Pathogenic Variant in External Auditory Canal Squamous Cell Carcinoma.Genes, chromosomes & cancer · 2026Article
- Tumor stage and treatment outcomes in external auditory canal SCC: a multicenter cohort study.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carcinoma of the external auditory canal (EAC) is rare, and squamous cell carcinoma (SCC) is the most common histological type. There are few reports on the treatment outcomes for a large number of cases at a single institution, and a standard treatment has not been established. Methods: Treatment details and prognoses were retrospectively examined for patients who underwent primary treatment for SCC of the EAC at The Jikei University between April 2015 and May 2023. Results: Twenty-seven patients with SCC of the EAC were included (median age of 64 years). Analysis using the revised Pittsburgh classification revealed that there were 3 cases of T1, 4 cases of T2, 9 cases of T3, and 11 cases of T4. Among the patients, 13 were treated surgically, 1 underwent partial resection of the EAC, 11 underwent lateral temporal bone resection, and 1 underwent subtotal temporal bone resection. The remaining 14 patients received nonsurgical treatment: 1 with radiotherapy, 3 with concurrent chemoradiotherapy, and 10 with induction chemotherapy (ICT). The overall survival (OS) and disease-free survival (DFS) rates at 3 years were 72.8% and 50.5%, respectively. When the surgical and non-surgical groups were compared, the 3-year OS and DFS rates were 92.3% and 68.3% for those who underwent surgery and 47.6% and 35.7% for those not treated with surgery, respectively, suggesting a better prognoses for patients who underwent surgical treatments ( Conclusion: At our institution, the 3-year OS and DFS rates of patients with SCC of the EAC were favourable for those who underwent surgery and received ICT. These findings suggest that treatment outcomes can be improved by using ICT in nonsurgical treatments for patients with SCC of the EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.